Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Clinical trial NCT01931566 · TERMINATED
Trial details
- NCT number
- NCT01931566
- Sponsor
- Takeda
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-08-01
- Primary completion
- 2018-07-24
- Enrollment
- 3494
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.